![]() |
|
|
Vol. 299, Issue 1, 147-158, October 2001
-Agonists on Cocaine
Pharmacodynamics and Cocaine Self-Administration in Humans
Behavioral Pharmacology Research Unit, Department of Psychiatry and
Behavioral Sciences, Johns Hopkins University School of Medicine,
Baltimore, Maryland
Preclinical studies have demonstrated that
-opioid agonists can
attenuate the neurochemical and behavioral effects of cocaine that are
related to its reinforcing efficacy, suggesting that
-agonists may
serve as pharmacotherapies for cocaine dependence. This 8-week
inpatient study examined the ability of enadoline, a selective and
high-efficacy
-agonist, and butorphanol, a mixed agonist with
intermediate efficacy at both µ- and
-receptors, to reduce the
direct pharmacodynamic effects and self-administration of intravenous
cocaine in humans (n = 8). Acute doses of
intramuscular enadoline (20, 40, and 80 µg/kg), butorphanol (1.5, 3, and 6 mg/70 kg) and placebo were examined separately as pretreatments
during each of three test sessions with cocaine in a constrained random order. A cocaine dose-effect session (0, 20, and 40 mg cocaine i.v.,
1 h apart) examined direct pharmacodynamic interactions on
subjective and physiological indices; self-administration sessions examined choice behavior for cocaine (40 mg i.v. for six trials) versus
money 1) in the presence of a sample cocaine dose with money choices
presented in ascending value, and 2) in the absence of a sample dose
with money choices presented in descending values. Enadoline (80 µg/70 kg) significantly (p < 0.05) reduced some of the positive subjective effects of cocaine (e.g., ratings of "high"), while butorphanol failed to modify subjective responses. Both agents were safely tolerated in combination with cocaine without
adverse physiological responses. Cocaine self-administration was
significantly greater across all pretreatment conditions when the
sample dose was given and ascending money choices were used. Enadoline
and butorphanol failed to modify cocaine self-administration. These
data suggest that these
-agonists may be safely administered in the
presence of cocaine but do not produce significant attenuation of
cocaine's direct effects or self-administration under these acute
dosing conditions.
This article has been cited by other articles:
![]() |
T. H. Kelly, W. W. Stoops, A. S. Perry, M. A. Prendergast, and C. R. Rush Clinical Neuropharmacology of Drugs of Abuse: A Comparison of Drug-Discrimination and Subject-Report Measures Behav Cogn Neurosci Rev, December 1, 2003; 2(4): 227 - 260. [Abstract] [PDF] |
||||